Connecting drug delivery reality to smart materials design

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 521-524

  Grainger, David W ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Analytical methods; Animal models; Drug delivery; Smart materials; Stimuli sensitive; Translational medicine

Indexed keywords

DRUG CARRIER;

ANALYTIC METHOD; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; IMAGING SYSTEM; NANOTECHNOLOGY; NOTE; PRIORITY JOURNAL;

EID: 84884162412     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.061     Document Type: Note

References (14)

1. Astashkina, A., Mann, B., Grainger, D.W., 2012. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol. Ther. 134, 82-106, http://dx.doi.org/10.1016/j.pharmthera.2012.01. 001.
2. Bae, Y.H., Park, K., 2011. Targeted drug delivery to tumors: myths, reality and possibility. J. Control Release 153, 198-205.
3. Crommelin, D.J.A., Florence, A.T., 2013. Towards more effective advanced drug delivery systems. Int. J. Pharm., http://dx.doi.org/10.1016/j.ijpharm.2013. 02.020.
4. Dubrovolaskia, M. (Ed.), 2013. Immunological Properties of Engineered Nanomaterials. World Scientific Press, Singapore.
5. Grainger, D.W., Castner, D.G., 2008. Nanobiomaterials and nanoanalysis: how to improve the nanoscience for biotechnology. Adv. Mater. 20, 867-877.
6. Jain, R.K., Stylianopoulos, T., 2010. Delivering nanomedicine to solid tumours. Nat. Rev. Clin. Oncol. 7, 653-664.
7. Johnston, H., Brown, D., Kermanizadeh, A., Gubbins, E., Stone, V., 2012. Investigating the relationship between nanomaterial hazard and physicochemical properties: informing the exploitation of nanomaterials within therapeutic and diagnostic applications. J Control Release 164, 307-313, http://dx.doi.org/10. 1016/j.jconrel.2012.08.018.
8. Jones, C.F., Grainger, D.W., 2009. In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 61, 438-456, http://dx.doi.org/10.1016/j.addr. 2009.03.005.
9. Kim, J.A., Åberg, C., Salvati, A., Dawson, K.A., 2012. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nanotechnol. 7, 62-68.
10. Kwon, I.K., Lee, S.C., Han, B., Park, K., 2012. Analysis on the current status of targeted drug delivery to tumors. J. Control Release 164, 108-114.
11. Lison, D., Huaux, F., 2011. In vitro studies: ups and downs of cellular uptake. Nat. Nanotechnol. 6, 332-333, http://dx.doi.org/10.1038/nnano.2011.81.
12. Spohn, P., Hirsch, C., Hasler, F., Bruinink, A., Krug, H.F., Wick, P., 2009. C60 fullerene: a powerful antioxidant or a damaging nanonoxe? The importance of an in-depth material characterization prior to toxicity assays. Environ. Pollut. 4, 1134-1139.
13. Taurin, S., Nehoff, H., Greish, K., 2012. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J. Control Release 164, 265-275, http://dx.doi.org/10.1016/j.jconrel.2012.07.013.
14. Teeguarden, J.G., Hinderliter, P.H., Orr, G., Thrall, B.D., Pounds, G.D., 2007. Particokinetics in vitro: dosimetryconsiderations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 95, 300-312, http://dx.doi.org/10.1093/toxsci/kfl165. (Pubitemid 46152602)